==> picture [665 x 116] intentionally omitted <==

THE ASX LEADER IN CELL THERAPY

TRANSFORMATIVE PORTFOLIO EXPANSION

CORE-NK Platform

Transformative Portfolio Expansion

A platform technology that can be leveraged to develop multiple new therapies

Broadens Chimeric’s reach into 10+ disease areas including blood cancers and solid tumours

Triples Chimeric’s pipeline adding 5 new cell therapy assets

Ability to further leverage the platform through partnerships or licensing

Extends Chimeric’s clinical development program with 5 new clinical trials by 2023

Propels Chimeric forward as the ASX leader in cell therapy and as an emerging global cell therapy company

==> picture [60 x 80] intentionally omitted <==

THE MOST ROBUST AND ADVANCED PORTFOLIO AND PIPELINE IN AUSTRALIA

==> picture [691 x 336] intentionally omitted <==

Unique Assets 8 Clinical Trials by 2023 10+ Disease Areas

CHIMERIC PIPELINE DEVELOPMENT STRATEGY

2 novel individualized (autologous) CAR T cell therapies
Exploration of opportunities with alternative cell types and cell sources

==> picture [629 x 335] intentionally omitted <==

----- Start of picture text -----

Novel Designs
T Cells
NK Cells
Individualized
(autologous)
CLTX CLTX CDH17
Phase 1 CAR T
CAR T CAR T
ongoing in
brain cancer Phase 1 Planned
Phase 1 Ongoing Off the Shelf
2022
(allogeneic)
----- End of picture text -----

WHY NATURAL KILLER (NK) CELLS?

Natural killer cells are superior immune cells

==> picture [255 x 250] intentionally omitted <==

Natural Killer (NK) Cell

Natural killer cells are part of our immune system and have a natural ability to identify and kill tumour cells. (they’re named for this “natural” killing ability) Natural killer cells are also able to produce cytokines that recruit and activate the immune system to mount an additional response to kill tumour cells.

Natural killer cells also have fail-safe mechanisms that prevent the killing of healthy cells making them ideal for off the shelf platforms.

WHY OFF THE SHELF?

Off the shelf therapies offer benefits and convenience to individualized therapies

==> picture [685 x 217] intentionally omitted <==

==> picture [960 x 99] intentionally omitted <==

----- Start of picture text -----

Healthier Scalable Rapidly Ability to
starting manufacturing available, reach more
material with reduced costs off the shelf patients
----- End of picture text -----

Early Stage, Off the Shelf, NK Cell Platforms are Driving Significant Value

==> picture [122 x 62] intentionally omitted <==

==> picture [115 x 57] intentionally omitted <==

==> picture [115 x 58] intentionally omitted <==

	nt Value	nt Value

Ph. 1 non-engineered NK cell platform Preclinical CAR NK products (2) $30M USD upfront + up to $1.8 B in milestones and royalties for to three CAR NK cell therapies targeting solid tumours Collaboration January 2021	Preclinical non-engineered NK cell platform $45M USD + undisclosed milestones and royaltiesfor up to four NK cell therapies Collaboration June 2021	Undisclosed upfront + $2.3B in milestones and royaltiesfor up to three CAR NK cell therapies Preclinical non-engineered NK cell platform Collaboration June 2021

Chimeric Therapeutics Off the Shelf, Natural Killer Cell Platform CORE-NK Platform Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform

INVESTMENT HIGHLIGHTS

CORE-NK PLATFORM

Clinically Validated, Off the Shelf, Robust, Enhanced, Natural Killer Cell Platform

§ An off the shelf, natural killer cell platform technology that will be leveraged to develop multiple new therapies
§ Clinical validation of the platform with a complete Phase 1 clinical trial in blood cancers and solid tumours
§ Platform enables near-term development of four additional Chimeric therapies for solid tumours and blood cancers
§ Synergistic with existing Chimeric assets, providing the ideal foundation to fast-forward development of CLTX CAR-NK and CDH17 CAR-NK therapies
§ Further ability to leverage the platform to build additional new therapies through partnerships or licensing
§ Phase 1 trials for new assets planned to begin in 2023
§ Off the shelf therapies and NK cells are highly attractive for investment and partnering
§ Attractive option terms with a planned research collaboration with Case Western

==> picture [62 x 194] intentionally omitted <==

THE CORE-NK PLATFORM A Novel Strategy to Enhance NK Cells Natural Abilities

==> picture [221 x 245] intentionally omitted <==

----- Start of picture text -----

David
WALD, MD, PhD
Associate Professor, Department
of Pathology, School of Medicine
Member, Immune Oncology Program,
Case Comprehensive Cancer Center,
Associate Director for Basic Research, University
Hospitals, Wesley Center for Immunotherapy
----- End of picture text -----

==> picture [216 x 59] intentionally omitted <==

Dr David Wald is a clinician-scientist at Case Western Reserve University in Cleveland, Ohio.

With an interest in cancer drug development Dr Wald has focused his research on using natural killer cells to eliminate colorectal cancer and acute myeloid leukemia.

Dr Wald developed a novel strategy to expand and activate NK cells ex vivo using a proprietary feeder cell line made him a CTP award recipient in 2018.

This engineered NK platform was specifically designed to overcome the hurdles often associated with NK cell development, including the ability to produce large numbers of highly active universal donor NK cells that maintain their activity once they’re in the body.

CORE-NK Platform Cells Enhancing the Natural Cancer-Fighting Power of NK cells

Natural Killer (NK) Cell

==> picture [403 x 203] intentionally omitted <==

==> picture [159 x 152] intentionally omitted <==

Natural killer cells are found in our bodies normally and are able to recognize and kill cancer cells- but are not robust and active enough to overcome cancer as it grows

CORE-NK Platform Cell

==> picture [182 x 187] intentionally omitted <==

==> picture [35 x 36] intentionally omitted <==

==> picture [36 x 36] intentionally omitted <==

==> picture [35 x 37] intentionally omitted <==

CORE-NK cells are made by activating and expanding natural killer cells to make them more active and robust in large quantities

CORE-NK PLATFORM PHASE 1 CLINICAL TRIAL

PATIENT ELIGIBILITY

==> picture [121 x 12] intentionally omitted <==

----- Start of picture text -----

BLOOD CANCERS
----- End of picture text -----

Acute Myeloid Leukemia Plasma Cell Myeloma Myelodysplastic Syndromes Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Chronic Lymphocytic Leukemia Myeloproliferative Syndromes Non-Hodgkin Lymphoma Hodgkin Lymphoma

==> picture [116 x 11] intentionally omitted <==

----- Start of picture text -----

SOLID TUMOURS
----- End of picture text -----

Adenocarcinoma of the Rectum Rhabdomyosarcoma Soft Tissue Sarcoma Ewing’s Sarcoma Colon Cancer

Phase 1 Clinical Trial Dr David Wald, Case Comprehensive Cancer Center Study Initiation : May 2018 Primary Completion : June 2021 Estimated Study Completion : May 2022

PHASE 1 DOSE ESCALATION

==> picture [197 x 294] intentionally omitted <==

CORE-NK PLATFORM (CHM 0201) PHASE 1 CLINICAL TRIAL COMPLETE

==> picture [859 x 270] intentionally omitted <==

----- Start of picture text -----

PRIMARY COMPLETION 11 PATIENTS ENROLLED 9 PATIENTS DOSED
JUNE 2021
SOLID TUMOURS COMPLETION OF ALL
DATA CURRENTLY PENDING AND BLOOD CANCERS 3 DOSE LEVELS
----- End of picture text -----

==> picture [218 x 15] intentionally omitted <==

----- Start of picture text -----

DATA ANTICIPATED 2022
----- End of picture text -----

CORE-NK PLATFORM (CHM 0201) WHAT DO WE DO WITH IT?

==> picture [290 x 298] intentionally omitted <==

----- Start of picture text -----

CHM 0 201
CORE-NK
Platform
----- End of picture text -----

Next Generation CORE-NK Platform

Further enhance the CORE-NK platform with next generation technologies for development as a combination therapy

CAR-NK Products

Fast-forward development of supercharged CAR NK products using our CLTX and CDH17 chimeric antigen receptors

Leverage the CORE-NK Platform Identify collaborations or licensing opportunities to further expand the utilization of the CORE-NK platform

CORE-NK PLATFORM (CHM 0201) WHAT DO WE DO WITH IT?

==> picture [290 x 298] intentionally omitted <==

----- Start of picture text -----

CHM 0 201
CORE-NK
Platform
----- End of picture text -----

1. Next Generation CORE-NK Platform

2. CAR-NK Products 3. Leverage the CORE-NK Platform

1. NEXT GENERATION CORE-NK Platform

Further enhancing the cancer-fighting power of the CORE-NK platform cells

==> picture [290 x 298] intentionally omitted <==

----- Start of picture text -----

CHM 0201
CORE-NK
Platform
----- End of picture text -----

==> picture [342 x 203] intentionally omitted <==

----- Start of picture text -----

Next Generation Enhancements
----- End of picture text -----

==> picture [292 x 298] intentionally omitted <==

----- Start of picture text -----

CHM 0301
Next Gen
CORE-NK
Platform
----- End of picture text -----

CHM 0301 NEXT GENERATION CORE-NK Platform Development in Blood Cancers as Combination Therapy

Acute Myeloid Leukemia

B Cell Malignancies

Multiple Myeloma

Cancer of the bone marrow and blood that generally progresses at a rapid pace
Incidence 4.3/ 100,000
2[nd] most common type of leukemia with ~100,000 new cases globally each year
5 year survival 24%
Type of non-Hodgkin lymphoma that originates in the B cells
• Incidence 8/ 100,000
• 85% of all non-Hodgkin lymphomas; includes diffuse large B cell lymphoma & follicular lymphoma
• 5 year survival ~69%
Cancer of the plasma cells in the bone marrow
Blood cancer of cells found in the bone marrow, specifically the “plasma cells.”
• Incidence: 5/ 100,000
• 5 year survival ~54%

2. CAR-NK PRODUCTS

HOW DO YOU TURN A CORE-NK CELL INTO A CAR-NK?

==> picture [136 x 67] intentionally omitted <==

CORE-NK CAR-NK Platform Cell Cell CAR-NK The Chimeric products are Antigen made by Receptor then inserting Insertion of Chimeric gets expressed Chimeric on the cell Antigen Antigen surface Receptors Receptor supercharging (CARs) into the the cells cancer CORE-NK fighting abilities platform cells

==> picture [102 x 77] intentionally omitted <==

Expression of Chimeric Antigen Receptors

CHIMERIC SUPERCHARGED CAR-NK PRODUCTS LEVERAGING OUR CHIMERIC ANTIGEN RECEPTORS

==> picture [161 x 50] intentionally omitted <==

==> picture [45 x 145] intentionally omitted <==

==> picture [279 x 232] intentionally omitted <==

----- Start of picture text -----

CLTX
CAR
CDH17
CAR
----- End of picture text -----

==> picture [45 x 145] intentionally omitted <==

==> picture [175 x 175] intentionally omitted <==

==> picture [113 x 83] intentionally omitted <==

==> picture [175 x 180] intentionally omitted <==

==> picture [118 x 83] intentionally omitted <==

CHM 1301 CLTX CAR-NK

CHM 2301 CDH17 CAR-NK

TRANSFORMATIVE PORTFOLIO DEVELOPMENT A DIVERSIFIED PIPELINE WITH CUTTING EDGE INNOVATION

==> picture [937 x 401] intentionally omitted <==

----- Start of picture text -----

Novel Design
NK Cells
T Cells
Autologous Allogeneic
(personal) (off-the-shelf)
CHM 0201 CHM 0301 CHM 1301 CHM 2301 CHM 3301
CHM 1101 CHM 2101
(CORE-NK (Next Gen. (CLTX (CDH17 (Undisclosed
(CLTX CAR T) (CDH17CAR T) CORE-NK
Platform) CAR-NK) CAR-NK) CAR-NK)
Platform)
Phase 1 Phase 1
Phase 1
ongoing planned 2022 Ph. 1 Planned Ph.1 Planned Ph.1 Planned Ph.1 Planned
Complete
2023 2023 2023 2023
----- End of picture text -----

LEVERAGE THE CORE-NK PLATFORM IDENTIFY COLLABORATION AND LICENSING OPPORTUNITIES

==> picture [67 x 37] intentionally omitted <==

==> picture [81 x 36] intentionally omitted <==

==> picture [87 x 44] intentionally omitted <==

==> picture [87 x 29] intentionally omitted <==

==> picture [56 x 40] intentionally omitted <==

==> picture [85 x 27] intentionally omitted <==

==> picture [78 x 32] intentionally omitted <==

==> picture [87 x 31] intentionally omitted <==

==> picture [84 x 36] intentionally omitted <==

==> picture [84 x 23] intentionally omitted <==

Development of 4 CAR NK / CAR T $50M upfront +$50M equity investment + products $3B milestones + double digit royalties $30M upfront + Development of 3 CAR NK products $612/ per CAR NK; $1.8B potential Undisclosed upfront + Development of 2 CAR iNKT products $875M USD milestones + royalties Development of 4 CAR NK products Undisclosed upfront, milestones and royalties Non-engineered NK cells Acquired by Sanofi $308 M EUROS

CORE-NK PLATFORM DEVELOPMENT PLAN 4 NEW CLINICAL TRIALS BY 2023

ü • • CORE-NK platform Phase 1 Phase 1 clinical trial: Next Development of CLTX CAR-NK
clinical trial completed at and CDH17 CAR-NK products generation CORE-NK platform Case Western • Phase 1 CAR NK clinical trial
• Initiate development of the • Identification of 3[rd] undisclosed (CLTX CAR-NK, CDH17 CARNext Generation CORE-NK CAR for development NK and undisclosed CAR-NK) platform
2021 2022 2023

ESTABLISHING VALUE IN THE NK DEVELOPMENT FIELD

Planned Time to Phase 1 Clinical Trial	Planned Time to Phase 1 Clinical Trial	Planned Time to Phase 1 Clinical Trial	Planned Time to Phase 1 Clinical Trial	Planned Time to Phase 1 Clinical Trial
Company	Market Cap	2021	2022	2023
	$90M AUS	CHM 0301(Next Generation CO CHM 0201 (CORE- NK) CHM 1301 (CLTX CAR-NK) CHM 2301 (CDH17 CAR-NK) CHM 3301(Undisclosed CAR-N	RE-NK) K)
	$948M USD	CD19 CD19+ CD79 CD133+ EGFR
	$5.0B USD	CD19 BCMA MICA A/B B7H3
	$851M USD	Enhanced NK Cells HER2
	$540M USD	NKG2D CD19 CD70
	$637M USD	Agent 797 BCMA Stromal Target

THE MOST EXPERIENCED CELL THERAPY TEAM IN AUSTRALIA GLOBAL EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALIZATION

==> picture [140 x 200] intentionally omitted <==

----- Start of picture text -----

Jennifer
CHOW
Chief Operating
Officer
----- End of picture text -----

==> picture [25 x 21] intentionally omitted <==

==> picture [38 x 17] intentionally omitted <==

==> picture [31 x 16] intentionally omitted <==

KITE PHARMA Head of Global Marketing, Commercial Operations and Analytics
CELGENE Global Cell Therapy Commercial Lead

==> picture [139 x 201] intentionally omitted <==

----- Start of picture text -----

Dr Syed
RIZVI
Chief Medical Officer
----- End of picture text -----

==> picture [25 x 22] intentionally omitted <==

==> picture [46 x 22] intentionally omitted <==

==> picture [49 x 8] intentionally omitted <==

LEGEND BIOTECH
VP, Clinical Development and Medical Affairs
CELGENE
Global Cell Therapy Medical Affairs Lead

Development of over CELL 25 THERAPIES including Dr Eliot Dr Li BOURK REN OF THE VP, Business and VP, Technical FDA-APPROVED 4/5 Corporate Development Operations CAR T CELL THERAPIES • KITE PHARMA • BMS Head of Early Global Manufacturing, Commercial Development Cell Therapy Development and Operations

• CELGENE Global Cell Therapy • CELGENE Commercial Strategy and CAR T CMC and Next Generation Platforms Technology Development

an Emerging Global Cell Therapy Company

A clinically validated, off the shelf NK platform technology that can be leveraged to develop multiple new therapies

Studied in a phase 1 clinical trial completed in June 2021 in both solid tumours and blood cancers

Enables the accelerated development of 4 Chimeric next generation, off the shelf NK and CAR-NK products

==> picture [126 x 167] intentionally omitted <==

Cutting edge cell therapy portfolio with 7 innovative assets using alternative cell types and sources

Advanced clinical development with 4 clinical trials by 2022 and 8 clinical programs by 2023

Broad development in 10+ disease areas including solid tumours and blood cancers

Additional opportunity for further development through internal development and/ or partnerships

Propels Chimeric forward as the ASX leader in cell therapy and as an emerging global cell therapy company

==> picture [529 x 105] intentionally omitted <==

AI assistant

CHIMERIC THERAPEUTICS LIMITED — Investor Presentation 2021

64648_rns_2021-11-30_e5936114-3021-44fa-ba93-55c4b63ec92b.pdf

THE ASX LEADER IN CELL THERAPY